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Background: Glutathione S-transferase (GST)M1, a member
of the m class GST gene family, has been shown to be
polymorphic because of a partial gene deletion. This results in
a failure to express the GSTM1 gene in 50–60% of individuals.
Several studies have demonstrated a possible link with the
GSTM1-null genotype and susceptibility to cancer. Further-
more, a GSTM1 isoenzyme has been positively associated with
protective effect against mutagenic drugs, such as alkylating
agents and anthracyclines.
Objectives: To determine whether GSTM1 polymorphisms are
associated with tumour characteristics and survival in
advanced breast cancer patients, and whether it may constitute
a prognostic factor.
Methods: We genotyped 92 patients receiving primary
chemotherapy, which included cyclophosphamide, doxo-
rubicine and 5-fluorouracil. The relationships between allelism
at GSTM1 and clinicopathological parameters including age,
menopausal status, tumour size, grade hormone receptors,
involved nodes and p53 gene mutations were analysed. Of the
patients with GSTM1-positive genotype, tissue samples
obtained before and after treatment were available from 28
cases, allowing RNA extraction and GSTM1 expression by
reverse transcription polymerase chain reaction. Relationships
with clinical response to chemotherapy, and disease-free and
overall survival were also evaluated. The data obtained were
analysed using logistic regression to estimate the odds ratio
and 95% confidence interval.
Results: Of 92 patients, 57.6% (n=53) were classified as
heritably GSTM1-deficient, and 42.4% (n=39) were of the
GSTM1-positive genotype. There were no statistically
significant relationships between GSTM1-null genotype and
the clinicopathological parameters analysed. No relationship
was observed between GSTM1 RNA expression and objective
clinical response to chemotherapy. Objective clinical response
to chemotherapy was related only to clinical tumour size
(P=0.0177) and to the absence of intraductal carcinoma
(P=0.0013). GSTM1-null genotype had no effect on disease-
free or overall survival. The absence of hormone receptors
(P=0.002), the presence of a mutated p53 gene (P=0.0098)
and lack of response to primary chemotherapy (P=0.0086)
were the only factors associated with reduced disease-free or
overall survival.
Conclusions: GSTM1-null genotype alone had no effect on
tumour characteristics and outcome of patients with advanced
breast cancers. The lack of correlation of GSTM1 genotype with
clinical tumour features, clinical response to chemotherapy and
survival exclude a role for GSTM1 polymorphism as a
prognostic factor in advanced breast cancer.
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Introduction
The human glutathione S-transferases (GSTs) are a multi-
gene, isoenzyme family. Cytosolic GST isoenzymes can
be classified by their substrate specificities, isoelectric
points and amino acid sequence homologies into major
classes termed a,  m,  p and  q, which are encoded by a
superfamily of genes located at different loci [1,2]. There
are currently five putative a class genes encoding subunits
GSTA1, GSTA2, GSTA3, GSTA4 and GSTw, whereas
the GST p class contains a single gene encoding the
GSTP1 protein, and the q class consists of two genes
encoding the GSTT1 and GSTT2 proteins.
The GSTM1 gene belongs to the GST m class gene family,
members of which are clustered on chromosome 1p13, and
which contains five genes encoding subunits GSTM1,
GSTM2, GSTM3, GSTM4 and GSTM5 [3,4]. The pres-
ence or absence of the GSTM1 gene constitutes the poly-
morphism, and the lack of the GSTM1 gene, which is
caused by a gene deletion (the GSTM1-null genotype),
affects approximately 50–60% of the population [5,6].
Homozygosity for the GSTM1-null genotype has been
found to confer risk for many cancers, including those of
the breast [7–17]. The GSTM1-null genotype was posi-
tively associated with high DNA adduct levels, suggesting
it has a role in carcinogenesis [7]. Smokers with a GSTM1
deficiency had a significantly elevated risk for developing
lung, laryngeal and bladder cancer [8,9]. The GSTM1-null
genotype has also been associated with higher risk for
environmentally related cancer, such as cancers of colon,
head and neck, skin, oesophagus and stomach [9–13].
For breast cancer, the GSTM1-null genotype has been
found to confer an increased risk in young post-
menopausal women [14], whereas other studies did not
find any association [18,19]. GST m deletions have been
reported to be associated with higher grade tumours [15],
however, and to confer accumulation of epoxides, which
are mutagenic [16]. GST isoenzymes catalyze the conjuga-
tion of glutathione to several electrophilic compounds,
including polyaromatic hydrocarbon, which is lipophilic
and stored in adipose tissues, such as those of the breast
[20]. Aromatic adducts were found to be higher in women
with breast cancer than in healthy control individuals [21].
Most polyaromatic compounds are metabolized to reactive
epoxide intermediates by the polymorphic cytochrome
p450 (CYP1AI) and detoxified by phase II enzymes,
including GST. The variation in conjugation of epoxide
substrate intermediates has been observed to segregate
with inherited loss of the GSTM1 gene. Therefore, indi-
viduals who inherit the homozygous form of the null poly-
morphism in the GSTM1 gene will not be capable of
conjugating and detoxifying specific substrate epoxide
intermediates [16]. In addition, a wide variety of alkylat-
ing chemotherapeutic agents used in the treatment of
breast cancer have been postulated to act as substrates for
the GSTM1 protein products, thus reducing the effective-
ness of these agents as cytotoxins [22].
In an attempt to further characterize the clinical features
associated with the GSTM1-null genotype, we examined
allelism at the GSTM1 locus in 92 locally advanced breast
cancer patients undergoing primary chemotherapy.
Allelism at the GSTM1 locus was analysed by polymerase
chain reaction (PCR) in paired samples of blood and
breast tissue. To determine whether levels of GSTM1
expression in patients with a positive genotype has a pre-
dictive or a prognostic value, RNA expression was mea-
sured by reverse transcription (RT)-PCR in breast tumour
samples obtained before and after treatment. Results were
then compared with clinicopathological factors of the
patients, including characterization for p53 gene mutations
[23], clinical response to chemotherapy, and disease-free
and overall survival.
Materials and methods
Patients and samples
After an initial diagnostic biopsy, including characterization
for p53 gene alterations, 92 women who were diagnosed
with locally advanced breast carcinoma and who under-
went primary chemotherapy were included in this study.
The median clinical follow up was 78months (range
10–120months). Three of these patients had bilateral
lesions, and in these three cases both lesions were exam-
ined. No family history for breast cancer was recorded in
the 92 women. The patients received chemotherapy treat-
ment (four or six courses, each lasting 21days) with a
regimen containing cyclophosphamide, doxorubicine and
5-fluorouracil. The criteria for inclusion were as follows:
inflammatory carcinomas, positive nodes and/or large (T3,
T4) tumours. Clinical response to primary chemotherapy
was categorized according to World Health Organization
criteria and was considered as objective response (com-
plete or partial response) or no response (stabilization or
progression). In all cases neither radiotherapy nor hormone
therapy were applied before chemotherapy.
Tumours were characterized before treatment by the clin-
ical tumour size (categorized as T2, T3 or T4); the clinical
nodal involvement (categorized as N0, N1 or N2); the his-
tologic grade of Scarff, Bloom and Richardson (categorized
as SBR1, SBR2 or SBR3); the hormone receptors (catego-
rized as HR– or HR+, and considered as positive for oestro-
gen and/or progesterone receptors); the pathological
tumour size (categorized as pT0, pT1, pT2 or pT3); and
the number of involved axillary nodes (categorized as pN–,
pN1+ and pN3+ for none, one or two, and three or more
involved nodes, respectively).
Peripheral blood lymphocytes were obtained from each
patient. Tumour samples were frozen in liquid nitrogen and
stored at –80°C until analysis. Genomic DNA was extracted83
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using proteinase, followed by phenol extraction and ethanol
precipitation according to standard procedures [24].
Polymerase chain reaction method
The GSTM1-null genotype was determined by coamplifi-
cation with the interferon-b gene, which served as an
internal control. Primers for amplification of the GSTM1
gene corresponding to exon 4, intron 5 and exon 5 were 5¢-
ctgccctacttgattgatggg-3¢ and 5¢-ctggattgtagcagatcatgc-3¢
(amplified product size, 271 base pairs). Primers for ampli-
fication of a part of the interferon-b gene, producing a con-
stant 170-base pair band in all samples, were
5¢-ggcacaacaggtagtaggcg-3¢ and 5¢-gccacaggagcttctgacac-3¢.
Because the primers for the GSTM1 locus anneal to sites
inside the coding region of the gene, the presence of the
gene was determined by the presence of the band,
whereas the null-genotype was determined by the lack of
the band, using agarose gel electrophoresis (2%).
PCR was performed using 250ng template DNA in
10mmol/l Tris-HCl (pH8.4), 50mmol/l potassium chloride,
1.5mmol/l magnesium chloride (Bioprobe Systems, Illkirch,
France), 0.2mmol/l concentrations of each deoxynucleotide
triphosphate (dNTP), 500nmol/l concentrations of each
primer and 2.5units of Taq DNA polymerase (Bioprobe
Systems). The reaction (total volume 50ml) was amplified
on a Omnigene thermal cycler (Hybaid Ltd, Ashford, Kent,
UK). After an initial denaturation at 94°C for 3 min the
reaction proceeded for 25 cycles of 50s at 94°C, 50s at 55°C
and 50s at 72°C, concluded by a final extension step of
10min at 72°C. To test for contamination, negative controls
(tubes containing the PCR mixture without the DNA tem-
plate) were included in every run.
Reverse transcription polymerase chain reaction
Total RNA was obtained by the acid guanidine thio-
cyanate–phenol–chloroform extraction method [25]. Of
the total RNA 1mg was dissolved in 20ml reverse tran-
scriptase buffer (Gibco/BRL, Cergy Pontoise, France)
containing 200mmol/l dNTP, 500 ng random hexamer and
200U avian myeloblastosis virus (AMV) reverse transcrip-
tase (Superscript; Gibco/BRL). The reaction was incu-
bated at 42°C for 50min and heated to 70°C for 15min. 
The PCR reaction was carried out in a 50ml volume of
PCR buffer (Promega, Madison, Wisconsin, USA) contain-
ing 200mmol/l dNTP, 2.5ml complementary DNA tem-
plate, 2.5U Taq DNA polymerase, and 500nmol/l of both
GSTM1 and b2-microglobulin primers. The reaction was
initiated by a heat step at 95°C for 2min, and carried out
for 25 cycles of denaturation at 94°C for 50s, annealing at
55°C for 50s and extension at 72°C for 50s. Blanks for
each reaction were included with all samples. Of PCR
product 10ml were analysed on a 2% agarose gel with
ethidium bromide staining. Band intensities were deter-
mined with a gel doc 1000 UV system (Biorad, Ivry-Sur-
Seine, France), and the ratio of GSTM1 to b2-microglobu-
lin was calculated.
Determination of p53 mutations
The determination of p53 mutations was performed as pre-
viously described [23]. Briefly, breast tumour samples were
characterized before and after treatment for p53 gene muta-
tions by PCR single-strand confirmation polymorphism
and/or direct sequencing of exons 5–9 of the p53 gene.
Hormonal receptor assay
The oestrogen and progesterone receptor levels were
determined in cytosolic tumours using enzyme immunoas-
say methods (Abbott Laboratories, Rungis, France). The
cutoff level used for oestrogen and progesterone was
20fmol/mg cytosolic proteins.
Statistical analysis
The Pearson c2 test was used as a homogeneity test for
proportion. A stepwise logistic regression model with the
logoistic regression (LR)-BMDP program (University of
California Press, Berkeley, California, USA) [26] was used
to assess the contribution of each independent factor to
the GSTM1-null genotype and the probability of response
to primary chemotherapy. The log-rank test using the
Kaplan–Meier method was used to study the relationship
between each factor and the probability of disease-free
survival (median 50months) and overall survival (median
78months). A multivariate analysis using the Cox propor-
tional hazards model was performed to assess the contri-
bution of each independent factor to the probability of
survival. For logistic regression or Cox regression models
the enter and remove limits were 0.1 and 0.15, respec-
tively. Overall significance of each factor (P value) was
given by the likelihood ratio test. Results are expressed as
odds ratios (OR) and corresponding 95% confidence inter-
val (CI), with the significance of ORs being derived from
the ratio of the coefficient divided by its standard error
(Wald test). Statistical analysis for RNA GSTM1 expres-
sion was performed using the SAS/STAT program (SAS
Institute Inc, Cary, North Carolina, USA) by using
Student  t-test or analysis of variance, Pearson c2 test and
log-rank test. For all tests, optimality of the selected
models was verified by all-possible-subsets analyses.
Results
Clinicopathological data
Patients (total 92) were characterized by two variables: age
and menopausal status at diagnosis. The median age of
these patients was 57 years, and status was premenopausal
for 51% (n=47) and postmenopausal for 48.9% (n=45). All
samples were composed of infiltrating ductal carcinoma
with an area of intraductual carcinoma in 35 cases. Of the
tumours, 33.7% (n=31) were 2–5cm in size (T2), 27.2%
(n=25) were >5cm (T3) and 39.1% (n=36/92) were >5cm
with skin involvement (T4). Of tumours, 60.9% (n=56)contained significant hormone receptors (HR+), and 39.1%
(n=36) did not (HR–). Clinical complete response was
found in 19.6% (n=18) of cases. A high histological grade
(SBR3) was found in 34.8% (n=32) of tumours. An inter-
mediate level of pathological tumour size (pT2) was found
in 42.4% (n=39) of samples. Negative lymph nodes were
found in 20.7% (n=19) of the tumours, whereas 23.9%
(n=22) of tumours were associated with >1 involved
nodes and 55.4% (n = 51/92) were associated with >3
involved nodes. Mutations in p53 were detected in 30%
(n=28) of the cases studied.
Glutathione S-transferase M1 genotype determination
The PCR method described above allowed an internal
standard controlled classification of GSTM1-deficient
(GSTM1-null genotype) individuals. Of the 92 patients,
57.6% (n=53) were classified as heritably GSTM1 defi-
cient, and 42.4% (n=39) were GSTM1-positive genotype.
Paired samples of blood and breast tissue were analysed
before treatment with primary chemotherapy from the
same individual, and GSTM1 genotype was identical for
the two samples (Fig. 1). Among the 39 patients with
GSTM1-positive genotype, tissue samples obtained
before and after treatment were available from 28 cases,
allowing RNA extraction and GSTM1 expression using the
RT-PCR method. Two of these patients had bilateral
lesions, and measurement was determined in the two
tumour localizations. Thus, total GSTM1 expression, as
measured by the ratio of GSTM1 to b2-microglobulin
values, were performed on 30 tumour specimens. GSTM1
RNA signal was detected in all of the tumours analysed
before and after treatment. The median GSTM1 expres-
sion was 1.38 (range 0.02–23.27) in the untreated tumours,
and 1.16 (range 0.01–6.56) in samples obtained after
chemotherapy administration.
Glutathione S-transferase M1 and clinicopathological
characteristics of the patients
Distribution of GSTM1 genotype and its relation with clini-
copathological data of the patients are shown in Table 1.
There were no statistically significant associations between
GSTM1-null genotype and the parameters analysed: age,
menopausal and hormonal status, clinical and pathological
tumour size, grade, involved nodes and p53 gene mutations.
GSTM1 expression measured by RT-PCR in 30 samples
(corresponding to 28 cases) before and after treatment with
primary chemotherapy was also compared with the clinico-
pathological characteristics of the patients. None of the
parameters tested were related to GSTM1 expression deter-
mined before or after treatment (data not shown).
Relationship to clinical response to chemotherapy (Table 2)
demonstrated that objective response (complete and partial
responses) rate of the group with GSTM1-null genotype
(75.5%) did not differ from that in those with GSTM1-posi-
tive genotype (76.9%). Thus, no significant relation was
found between GSTM1 polymorphism and clinical
response to chemotherapy (P=0.8719). Also, no relation was
observed between GSTM1 RNA expression and clinical
response to chemotherapy (P=0.9524 and P=0.5192 for
before and after treatment, respectively). In contrast, clinical
tumour size (P=0.0177) and intraductal carcinoma
(P=0.0013) are strongly associated with clinical response. In
multivariate analysis, the clinical tumour size (P=0.0070,
OR=4.83, 95% CI=1.45–16.10) and the absence of intraduc-
tal carcinoma (P=0.0002, OR=14.1, 95% CI=2.52–78.50)
remained the only factors linked to the clinical response.
Impact on survival of the patients
For disease-free survival, no differences were found
between individuals with GSTM1-null genotype and
those with positive-GSTM1 genotype (P=0.8094).
Accordingly, no impact for RNA GSTM1 expression on
disease-free survival (P=0.8991 and P=0.9096 for before
and after treatment, respectively) was observed (Table 2).
In contrast, the absence of hormone receptors (P=0.0020)
and the presence of p53 gene mutations (P=0.0098) had
an impact on disease-free survival. With multivariate
analysis, hormone receptor status (P=0.0002, OR=3.99,
95% CI=1.92–8.29) and p53 gene mutations (P=0.0138,
OR=2.36, 95% CI=1.22–4.59) remained significantly
associated with metastasis recurrence risk.
No impact was also found (P=0.9729) for GSTM1-null
genotype on overall survival (Table 2), or for RT-PCR
RNA expression (P=0.1667 and P=0.9637 for before and
after treatment, respectively). Only the absence of hormone
receptors (P=0.0018), the presence of p53 gene mutations
(P=0.0071) and no response to primary chemotherapy
(P=0.0086) were associated with reduced overall survival of
the patients. In multivariate analysis, hormone receptor
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Figure 1
Polymerase chain reaction product of paired lymphocyte (L) and
tumour (T) DNA from coamplification of glutathione S-transferase
(GST)M1 (271 base pair) and interferon-b (170 base pair) genes.
Lane 1 shows a homozygously present GSTM1 allele. Lane 2 shows a
homozygously null-GSTM1 allele. M1 is FX174-HaeIII digested DNA
marker. M2 is FX174-HinfI digested DNA marker.
LT LT
271 bp
170 bp
300 bp
200 bp
M1 1 2 M2status (P=0.0003, OR=5.23, 95% CI=2.03–13.49) and p53
gene mutations (P=0.0037, OR=3.62, 95% CI=1.53–8.53)
were strongly related to the risk for death. Absence of clini-
cal response to chemotherapy was less related to the overall
survival (P=0.0530, OR=2.31, 95% CI=1.02–5.26).
Discussion
In the present study, the frequency of GSTM1 gene defi-
ciency among breast carcinoma patients (57%) was similar
to that previously reported in this lesion [9,14–19]. Among
individuals with GSTM1-positive genotype no deletion
was observed in somatic tumour cells, suggesting that the
deletion of GSTM1 gene was not a characteristic of breast
tumour cells.
Several series have determined that GSTM1 deletions
were involved in the aetiology of breast cancer [9,14,17],
whereas other studies did not find any such associations
[18,19]. In addition, little is known about clinical charac-
teristics that confer GSTM1 deletion among breast cancer
patients. Only one recently published study [19] reported
no relation between clinicopathological parameters and
GSTM1 genotype in primary breast tumours. The results
obtained in the present study are consistent with these
data, because no differences were noted when a variety of
known prognostic factors were compared between
tumours from patients with and those without GSTM1-
null genotype. These factors include age, menopausal
status, clinical and pathological tumour size, clinical and
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Table 1
Association of glutathione S-transferase (GST)M1 genotype and clinicopathological data of breast cancer patients studied
GSTM1
Parameters Variables Present Null OR (95% CI)
Age (years) <50 22 28
>50 17 25 1.99 (0.531–7.44)
Status Premenopausal 22 23
Postmenopausal 17 30 0.59 (0.22–1.61)
Clinical tumour size T2 15 16
T3 + T4 24 37 1.7 (0.62–4.52)
Clinical nodal involvement N0  14 11
N1 + N2 25 42 3.02 (0.97–9.89)
Histologic grade SBR1 8 6
SBR2 + 3 31 47 2.4 (0.66–9.02)
Hormone receptors HR– 17 19
HR+ 22 34 1.04 (0.38–2.80)
Pathological tumour size pT0 + pT1 19 26
pT2 + pT3 20 24 0.8 (0.32–2.08)
Involved nodes pN– 10 9
pN1+ pN3+ 29 54 2.05 (0.67–6.27)
p53 Normal 31 33
Mutated 8 20 2.7 (0.88–7.90)
CI, confidence interval; OR, odds ratio.
Table 2
Clinical response to primary chemotherapy and breast cancer outcome
GSTM1
Parameters Present Null P
Objective response* 76.9% 75.5% 0.8719†
Disease-free survival (months) 42.00 ± 2.65 54.43 ± 5.67 0.8094‡
Overall survival (months) 74.82 ± 3.95 72.73 ± 4.81 0.9729‡
*Objective response was estimated as complete and partial
responses. †Estimated by Pearson c2 test. ‡Estimated by log rank test,
median±standard error. GST, glutathione S-transferase.pathological nodal involvement, pathological grade,
hormone receptors status and p53 gene mutations. These
results suggest that clinical tumour features are not associ-
ated with GSTM1-null genotype, not only in primary
breast cancers, but also in advanced breast cancers.
An improved survival has been observed in patients with
GSTM1-null genotype and has been explained by a
better response to chemotherapeutic agents related to
more effective cell killing, which in turn is related to the
absence of a protective effect of the GSTM1 allele [18].
Among the most active chemotherapeutic agents in the
treatment of breast cancer are cyclophosphamide and
anthracyclines. These compounds are conjugated with
thiols through reactions mediated by GST. The p class of
transferase is thought to be the major factor involved in
the subsequent prevention of DNA alkylation [22],
although there has been some suggestion that the m class
is also involved [27]. In order to determine whether the
absence of GSTM1 locus favours the response to
chemotherapeutic agents, and whether, on the contrary,
GSTM1-positive genotype may confer a resistance to
chemotherapy, we analysed GSTM1 polymorphisms in
relation to clinical response to chemotherapy. The results
demonstrated that the objective response rate of the
group with GSTM1-null genotype did not differ from
those with GSTM1-positive genotype. Thus, individuals
carrying the GSTM1 locus were no more resistant to
chemotherapy than those with GSTM1-null genotype.
GSTM1 RNA expression levels measured in patients with
positive genotype were also not associated with clinical
response to chemotherapy. Among clinical parameters
analysed, only clinical tumour size and the presence of
intraductal carcinoma were found to influence clinical
response to primary chemotherapy. The results also
revealed that GSTM1-null genotype was not related to
survival in advanced breast cancer patients, in contrast to
the absence of hormone receptors and to the presence of
p53 gene mutations, which are known to be of prognostic
value in advanced breast cancer [28–30].
Although the group studied was not very large (n=92), the
clinical characteristics were well known and the results
strongly suggest the lack of correlation of GSTM1-null
genotype alone with prognostic factors, clinical reponse to
chemotherapy and survival. Genotypes of other enzymes
(CYP1A1, GSTT1), as well as combinations of genotypes,
might be of interest with regard to cancer and carcinogen
metabolism.
Taken together, these results show that advanced breast
cancers arising in patients with GSTM1-null genotype
have no worse clinical tumour characteristics and outcome
than those of patients without such deletions. Thus, the
lack of correlation of GSTM1-null genotype with clinical
tumour features, clinical response to chemotherapy and
survival exclude a role for GSTM1 polymorphism as a
prognostic factor in advanced breast cancer.
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